Principal Investigator: E. Scott Stibitz, PhD
Office / Division / Lab: OVRR / DBPAP / LESTD
Our laboratory is studying disease-causing bacteria for which new vaccines and novel therapeutic approaches are being developed.
We are developing new ways to study respiratory infections caused by the bacterium Bordetella pertussis (whooping cough) and the mechanisms by which it causes severe disease. Although a vaccine for this organism exists, the number of whooping cough cases in the US continues to rise, making this research vital to ultimate control.
We also support the development and evaluation of vaccines against Staphylococcus aureus, which causes many infections in the US each year, some of which are extremely serious (e.g., "flesh-eating" bacteria that can cause death in a matter of hours). S. aureus also causes infections of implanted devices such as pacemakers and joint replacements that can be very difficult to treat without removing the device. Currently no vaccine for this disease exists and development of new vaccines against this organism is especially critical due to problems with antibiotic resistance typified by MRSA (methicillin-resistant Staphylococcus aureus), and the new strains of community-acquired MRSA (CA-MRSA).
We also study live biotherapeutic products (i.e., probiotics--live microorganisms that provide health benefits to an individual when consumed in appropriate quantities) to help treat and prevent bacterial infections and other conditions. The investigation of the full potential of these promising products is currently being hindered by difficulties in evaluation of the manufacturing process, purity, safety and quality of these products. We seek to solve this problem by developing better tests for the purity and safety of probiotics, thereby allowing their further testing and development in the clinic.
Diarrheal diseases are also targetted. We are investigating the use of the live attenuated Salmonella strain Ty21a as a platform for eliciting protective immune responses against other serious diseases such as Shigellosis. We are also examining ways to more fully understand some of the as yet uncharacterized genetic bases of attenuation in Ty21a as well as to confer advantageous traits such as acid resistance. We are also seeking to understand why some bacterial pathogens, such as Shigella can cause arthritis and are testing novel approaches to killed Shigella vaccines in order to control this deadly disease.
Another major worldwide health challenge and emerging problem in the US - tuberculosis - is in a class by itself in terms of its difficulty to study, its overall importance, its resistance to date to vaccine interventions, and the threat from antibiotic resistance. Our lab is working to develop and execute new ways to assess the usefullness of vaccine candidates, including the development of animal models and of in vitro tests to measure host responses.
Malaria, while not a bacterial disease, in one which also has a huge worldwide burden. Recent exciting research has brought us much closer to having a useful anti-malaria vaccine. Our lab is studying biomarkers for severe malaria in an effort to both better understand the variables that can lead to tragic outcomes as well as to better assess how current vaccine candidates control disease and infection.
Our laboratory takes a genetic approach to studies of bacterial pathogenesis and vaccine development.
In our studies of Bordetella pertussis we introduce specific mutations that affect the expression and regulation of virulence factors, such as toxins and adhesins. We then test the effects of these mutations in a mouse model of respiratory infection that uses bioluminescent B. pertussis to track infection without harming the test animal. This approach has several advantages over older methods that involve sacrificing a group of test animals at each time point, and reduces dramatically the number of animals that must be used.
Our approach to studying Bacillus anthracis pathogenesis has also been largely genetic. We developed and have recently improved, new genetic tools to introduce specific mutations into this organism. These tools, which are now used widely around the world, are significantly easier and more powerful than previous such techniques. They also allow the consecutive deletion or mutation of a unlimited number of genes. This approach has been critical to our studies of anthrax vaccine stability. For example, it has enabled us to create improved strains of the organism used to produce protective antigen (part of the anthrax toxin). These strains lack a number of secreted proteases (currently up to 16 separate deletions). This characteristic increases the production of protective antigen and leads to a purified product that has increased stability.
Our new program in Staphylococcus aureus will follow a similar path, synergizing our genetic capabilities with other OVRR researchers to evaluate new vaccine candidates and identify new candidates for virulence factors and vaccine antigens. We are also examining the utility of a novel approach - bacteriophage therapy - to deal with antibiotic resistant S. aureus.
We are using bacteriophages to develop improved tests for detecting pathogens in probiotic products. We plan to exploit the exquisite specificity of these bacterial viruses to specifically kill product organisms, thereby increasing the sensitivity of detection of extraneous and potentially harmful bacterial pathogens, such as Salmonella and Shigella. Such tests are necessary to ensure the safety of these preparations, a factor that is especially important when tested in clinical trials in very sick or otherwise compromised patients.
Another application of bacteriophages is to actually treat bacterial diseases. Our lab is initiating a project to set up an animal model to examine the usefullness of phage in host decolonization of Staphylococcus aureus. If successful, this could have a major impact on carriage in hospitals and significantly improve the situation there where dangerous, highly antibiotic strains, MRSA, have a high toll.
Antimicrob Agents Chemother 2020 Sep;64(9):e00993-20
Bacteriophage-antibiotic combinations for enterococcus faecium with varying bacteriophage and daptomycin susceptibilities.
Morrisette T, Lev KL, Kebriaei R, Abdul-Mutakabbir J, Stamper KC, Morales S, Lehman SM, Canfield GS, Duerkop BA, Arias CA, Rybak MJ
Biologicals 2020 Jul;66:53-61
Human challenge trial workshop: focus on quality requirements for challenge agents, Langen, Germany, October 22, 2019.
Bekeredjian-Ding I, Van Molle W, Baay M, Neels P, Conrad C, van Diepen A, Fortune S, Goetz K, Gorringe A, Hoft D, Johnson RA, Kremsner P, Krut O, Levy Y, Metzger W, Oeppling V, Stibitz S, Talaat KR, Thomas S, Wildfire A, Yakubu BN
Antimicrob Agents Chemother 2020 Jul;64(7):e00461-20
Bacteriophage-antibiotic combination strategy: an alternative against methicillin-resistant phenotypes of Staphylococcus aureus.
Kebriaei R, Lev K, Morrisette T, Stamper K, Abdul-Mutakabbir JC, Lehman S, Morales S, Rybak MJ
PLoS Pathog 2020 May 13;16(5):e1008500
Multiple weak interactions between BvgA~P and ptx promoter DNA strongly activate transcription of pertussis toxin genes in Bordetella pertussis.
Chen Q, Boucher PE, Stibitz S
Materials 2019 Dec 5;12(24):4052
Complete killing of agar lawn biofilms by systematic spacing of antibiotic-loaded calcium sulfate beads.
Dusane DH, Brooks JR, Sindeldecker D, Peters CW, Li A, Farrar NR, Diamond SM, Knecht CS, Plaut RD, Delury C, Aiken SS, Laycock PA, Sullivan A, Granger JF, Stoodley P
Vaccine 2019 Jul 18;37(31):4256-61
Use of controlled human infection models (CHIMs) to support vaccine development: US regulatory considerations.
Ramanathan R, Stibitz S, Pratt D, Roberts J
mSphere 2019 May 22;4(3):e00694-18
In vivo gene essentiality and metabolism in bordetella pertussis.
Gonyar LA, Gelbach PE, McDuffie DG, Koeppel AF, Chen Q, Lee G, Temple LM, Stibitz S, Hewlett EL, Papin JA, Damron FH, Eby JC
Curr Opin Microbiol 2019 Feb;47:74-81
The BvgASR virulence regulon of Bordetella pertussis.
Chen Q, Stibitz S
MBio 2019 Jan 8;10(1):10:e02491-18
Corynebacterium pseudodiphtheriticum exploits Staphylococcus aureus virulence components in a novel polymicrobial defense strategy.
Hardy BL, Dickey SW, Plaut RD, Riggins DP, Stibitz S, Otto M, Merrell DS
Front Immunol 2018 Nov 9;9:2612
TACI contributes to Plasmodium yoelii host resistance by controlling T follicular helper cell response and germinal center formation.
Parra M, Yang J, Weitner M, Derrick S, Yang A, Schmidt T, Singh B, Moreno A, Akkoyunlu M
J Bacteriol 2018 Sep 24;200(20):e00175-18
A novel Bvg-repressed promoter causes vrg-like transcription of fim3 but does not result in the production of serotype 3 Fimbriae in the Bvg(-) mode Bordetella pertussis.
Chen Q, Lee G, Craig C, Ng V, Carlson PE Jr, Hinton DM, Stibitz S
Emerg Infect Dis 2018 Apr;24(4):691-9
Avirulent Bacillus anthracis strain with molecular assay targets as surrogate for irradiation-inactivated virulent spores.
Plaut RD, Staab AB, Munson MA, Gebhardt JS, Klimko CP, Quirk AV, Cote CK, Buhr TL, Rossmaier RD, Bernhards RC, Love CE, Berk KL, Abshire TG, Rozak DA, Beck LC, Stibitz S, Goodwin BG, Smith MA, Sozhamannan S
Clin Vaccine Immunol 2017 Dec 5;24(12):e00181-17
Stable chromosomal expression of Shigella flexneri 2a and 3a O-antigens in the live Salmonella oral vaccine vector Ty21a.
Dharmasena MN, Osorio M, Takeda K, Stibitz S, Kopecko DJ
J Infect Dis 2017 Nov 15;216(10):1264-72
A novel gametocyte biomarker for superior molecular detection of the Plasmodium falciparum infectious reservoirs.
Essuman E, Grabias B, Verma N, Chorazeczewski JK, Tripathi AK, Mlambo G, Addison EA, Amoah AGB, Quakyi I, Oakley MS, Kumar S
Cell Host Microbe 2017 Nov 8;22(5):653-66
Staphylococcus aureus epicutaneous exposure drives skin inflammation via IL-36-mediated T cell responses.
Liu H, Archer NK, Dillen CA, Wang Y, Ashbaugh AG, Ortines RV, Kao T, Lee SK, Cai SS, Miller RJ, Marchitto MC, Zhang E, Riggins DP, Plaut RD, Stibitz S, Geha RS, Miller LS
Genome Announc 2017 Nov 9;5(45):e01231-17
Whole-genome sequences of variants of Bacillus anthracis Sterne and their toxin gene deletion mutants.
Staab A, Plaut RD, Pratt C, Lovett SP, Wiley MR, Biggs TD, Bernhards RC, Beck LC, Palacios GF, Stibitz S, Jones KL, Goodwin BG, Smith MA, Sozhamannan S
J Bacteriol 2017 Oct 17;199(22):e00475-17
Activation of Bvg-repressed genes in Bordetella pertussis by RisA requires cross-talk from a non co-operonic histidine kinase RisK.
Chen Q, Ng V, Warfel JM, Merkel TJ, Stibitz S
MBio 2017 Oct 10;8(5):e01526-17
The BvgAS regulon of Bordetella pertussis.
Moon K, Bonocora RP, Kim DD, Chen Q, Wade JT, Stibitz S, Hinton DM
Microbiol Spectr 2017 Sep;5(5):BAD-0017-2017
U.S. regulatory considerations for development of live biotherapeutic products as drugs.
Dreher-Lesnick SM, Stibitz S, Carlson PE Jr
NPJ Vaccines 2017 Jun 15;2:17
Protection against inhalation anthrax by immunization with Salmonella enterica serovar Typhi Ty21a stably producing protective antigen of Bacillus anthracis.
Sim BKL, Li ML, Osorio M, Wu Y, Wai TT, Peterson JW, James ER, Chakravarty S, Gao LX, Xu R, Natasha KC, Stafford RE, Lawrence WS, Yeager LA, Peel JE, Sivasubramani SK, Chopra AK, Filippova S, Hoffman SL
Proc Natl Acad Sci U S A 2017 Feb 21;114(8):E1519-27
Bordetella PlrSR regulatory system controls BvgAS activity and virulence in the lower respiratory tract.
Bone MA, Wilk AJ, Perault AI, Marlatt SA, Scheller EV, Anthouard R, Chen Q, Stibitz S, Cotter PA, Julio SM
Clin Vaccine Immunol 2017 Jan 5;24(1):e00509-16
Trained immunity and susceptibility to HIV.
PLoS One 2016 Dec 2;11(12):e0166814
Molecular markers of radiation induced attenuation in intrahepatic Plasmodium falciparum parasites.
Oakley MS, Verma N, Zheng H, Anantharaman V, Takeda K, Gao Y, Myers TG, Pham PT, Mahajan B, Kumar N, Sangweme D, Tripathi AK, Mlambo G, Aravind L, Kumar S
Pathog Dis 2016 Nov;74(8):ftw098
Stable expression of Shigella dysenteriae serotype 1 O-antigen genes integrated into the chromosome of live Salmonella oral vaccine vector Ty21a.
Dharmasena MN, Osorio M, Filipova S, Marsh C, Stibitz S, Kopecko DJ
PLoS One 2016 Sep 27;11(9):e0163511
Development of an Acid-Resistant Salmonella Typhi Ty21a Attenuated Vector For Improved Oral Vaccine Delivery.
Dharmasena MN, Feuille CM, Starke CE, Bhagwat AA, Stibitz S, Kopecko DJ
J Microbiol Methods 2016 Dec;131:7-9
A simplified mycobacterial growth inhibition assay (MGIA) using direct infection of mouse splenocytes and the MGIT system.
Yang AL, Schmidt TE, Stibitz S, Derrick SC, Morris SL, Parra M
Sci Rep 2016 Sep 13;6:32774
The multifaceted RisA regulon of Bordetella pertussis.
Coutte L, Huot L, Antoine R, Slupek S, Merkel TJ, Chen Q, Stibitz S, Hot D, Locht C
Clin Vaccine Immunol 2016 Jul 5;23(7):638-47
Induction of unconventional T cells by a mutant BCG strain formulated in cationic liposomes correlates with protection against M. tuberculosis infections of immunocompromised mice.
Derrick SC, Yabe I, Morris S, Cowley S
Viruses 2015 Dec 16;7(12):6675-88
Development of phage lysin LysA2 for use in improved purity assays for live biotherapeutic products.
Dreher-Lesnick SM, Schreier JE, Stibitz S
PLoS One 2015 Dec 1;10(12):e0142758
Improvements to a markerless allelic exchange system for Bacillus anthracis.
Plaut RD, Stibitz S
PLoS One 2015 Oct 27;10(10):e0141141
Co-expression of Interleukin-15 enhances the protective immune responses induced by immunization with a murine malaria MVA-based vaccine encoding the circumsporozoite protein.
Parra M, Liu X, Derrick SC, Yang A, Molina-Cruz A, Barillas-Mury C, McGavern DB, Zheng H, Thao Pham P, Sedegah M, Belmonte A, Litilit DD, Waldmann TA, Kumar S, Morris SL, Perera LP
Proc Natl Acad Sci U S A 2015 Feb 10;112(6):E526-35
Bordetella pertussis fim3 gene regulation by BvgA: Phosphorylation controls the formation of inactive vs. active transcription complexes.
Boulanger A, Moon K, Decker KB, Chen Q, Knipling L, Stibitz S, Hinton DM
Vaccine 2015 Jan 1;33(1):126-32
Effect of cationic liposomes on BCG trafficking and vaccine-induced immune responses following a subcutaneous immunization in mice.
Derrick SC, Yang A, Parra M, Kolibab K, Morris SL